April 24, 2023 Print
A gene that controls the cut-off switch for kidney inflammation could pave the way for more precise disease diagnostics and personalised treatments.
A discovery about gene variants of an inflammation ‘brake’ brings scientists a step closer to personalised treatment for patients at risk of kidney disease and kidney failure.
WIMR's Professor Natasha Rogers co-lead the study, collaborating with researchers at the Garvan Institute of Medical Research, University of New South Wales, Sydney and Westmead Hospital, and found that common genetic variants of TNFAIP3
, which increase inflammation in the body, can paradoxically protect the kidneys from damage in the short term.
“We wanted to investigate whether inherited differences in how people regulate inflammation could lead to better or worse kidney health outcomes,” says Professor Shane Grey, senior author of the paper and Head of the Transplant Immunology Lab at Garvan.
“We focused on the TNFAIP3
gene, which produces a protein called A20 that acts as a ‘brake’ on inflammation. Common variants of TNFAIP3
have been linked to autoimmune disease, but their role in kidney disease was unknown. Our discovery that some genetic variants can be protective against inflammation could lead to a simple genetic test that helps predict the risk of kidney disease for patients.”
Unexpected protective effect of pro-inflammatory variant
Acute kidney injury – a sudden and rapid decline in kidney function that is in part caused by inflammation – is an important risk factor for progression to chronic kidney disease, a major health problem affecting approximately one in 10 Australians. Currently there are limited treatment options for acute kidney injury, and imprecise tools to predict who is most at risk of poor recovery or kidney failure.
The team first investigated how different TNFAIP3
variants influence A20's function, finding a series of rare variants that reduced its anti-inflammatory effect. They then tested the effects of one of the variants that promotes inflammation during kidney injury in a mouse model.
Professor Natasha Rogers is Deputy Director of WIMR’s Centre for
Transplant and Renal Research, and leads the Kidney Injury Research Group and co-led the study. She says, “Despite increasing inflammation, this rare variant surprisingly protected the kidneys from injury. We found this protection to be due to another of A20’s functions: preventing cells from self-destructing.”
“Our study indicates that these ‘hot’ TNFAIP3
variants can alter the outcome of kidney injury, and they do so through complex effects on inflammation and cell survival.”
The findings are published in the journal Kidney International
New treatment approaches on the horizon
“More work is needed, but these findings bring us closer to being able to predict who is at risk of poor kidney recovery, and open personalised treatment approaches,” says Professor Grey.
The study could lead to a simple genetic test to allow doctors to determine whether an individual carries a ‘hot’ version of the inflammation control gene, giving families greater certainty about their risk factors.
“By gaining a better understanding of how variants of the TNFAIP3
gene influence kidney health, this research brings us closer to precision diagnostics and tailored treatments for acute kidney injury,” says Professor Grey. “Rather than a one-size-fits-all approach, we may be able to determine the best way to monitor a patient’s condition based on their variant of TNFAIP3
, and personalise interventions to boost their kidney recovery and long-term health.”